Stander S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, Williams N, Sciascia T, Augustin M. Worst itch numerical rating scale for Prurigo Nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):573-81. doi: 10.1111/jdv.17870
Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-9. doi: 10.1111/jdv.15047
Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094
Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Brookhart MA. Injection testosterone and adverse cardiovascular events: a case-crossover analysis. Clin Endocrinol (Oxf). 2018 May;88(5):719-27. doi: 10.1111/cen.13574
Hunter JE, Arnold KA, Cook JE, Zepp J, Gilmore MJ, Rope AF, Davis JV, Bergen KM, Esterberg E, Muessig KR, Peterson SK, Syngal S, Acheson L, Wiesner G, Reiss J, Goddard KAB. Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Fam Cancer. 2017 Jul;16(3):377-87. doi: 10.1007/s10689-017-9972-2
Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D, Papavassillis C, Gelfand J. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9. doi: 10.1111/jdv.13478
Godwin SL, Coppings R, Kosa KM, Cates SC. Consumer response to food contamination and recalls: findings from a national survey. J Food Distrib Res. 2012 Mar;43(1):19-26. doi: 10.22004/ag.econ.139445
Huang K, Gutierrez LP, Bulow S, Gallinger S, Castells A, Eagle CJ, Church JM. Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study. Fam Cancer. 2011 Jun 1;10(2):303-8.
Alvarez-Pedrerol M, Ribas-Fito N, Garcia-Esteban R, Rodriguez A, Soriano D, Guxens M, Mendez M, Sunyer J. Iodine sources and iodine levels in pregnant women from an area without known iodine deficiency. Clin Endocrinol (Oxf). 2010 Jan;72(1):81-6. doi: 10.1111/j.1365-2265.2009.03588.x
McKennas SP, Whalley D, deProst Y, Staab D, Huels J, Paul CF, vanAssche D. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol. 2006 Mar 1;20(3):248-54.
Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P. Measuring quality of life in lupus: development of the SLEQoL. Poster presented at the First EADV International Spring Symposium; February 2003. [abstract] J Eur Acad Dermatol Venereol. 2003 Mar; 17(Suppl 1):58.
Wirén L, Whalley D, McKenna SP, Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by Rasch analysis. Clin Endocrinol (Oxf). 2000 Feb;52(2):143-52.
McKenna S, Doward LC. Measuring quality of life in adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1996 Oct;45(4):507-8.